CBD /

 

Loading...
Country's Decision or any other Communication (DEC)
  |  
BCH-DEC-BR-299617-1   |   PDF   |   Print   |  
| 
|  Close
last updated: 25 Jun 2026
Amendment
No
General Information
Commercial Release of the INNOVAX ILT Vaccine - Technical Opinion No. 2872/2011.
EN
31 Aug 2010
No
Subject of the decision, notification, communication or declaration
  • Decision on LMOs for intentional introduction into the environment (according to Article 10 or domestic regulatory framework)
  • Decision on LMOs for direct use as food or feed, or for processing (Article 11, LMOs-FFP)
LMOs for intentional introduction into the environment
No
Yes
Yes
Yes
Yes
LMOs for direct use as food or feed, or for processing (LMOs-FFP)
  • LMOs for processing
No
Result of the decision
Approval of the import and/or use of the LMO(s) without conditions
LMO identification & risk assessment
  • BCH-LMO-SCBD-114985-1 Living Modified Organism INNOVAX®-ILT
    MSD Animal Health | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
  • BCH-RA-BR-299525-1 Risk Assessment generated by a regulatory process Risk assessment of the INNOVAX ILT Vaccine - Technical Opinion No. 2872/2011.
    INNOVAX®-ILT | Turkey herpesvirus, Meleagrid herpesvirus 1, Production of medical or pharmaceutical compounds (human or animal)
Document on the decision, communication, notification or declaration

Quick links

About the BCH About the Cartagena Protocol Supplementary Protocol

Sign in Search records Submit records
Registries: LMO-Organism-Gene Country Profiles
National Report Analyzer

Forums BCH Announcements

Need help?

Knowledge Base FAQs UNEP eLearning Training Site

Contact us at: bch@cbd.int
BCH Biosafety Clearing-House
Subscribe to e-mail notifications
Subscribe to our newsletter